Humana Has a Stars Windfall. It Won't Tell You How Big.

The $9.50 Is Not the Story

Humana's third-quarter call opened with a sentence that could have come from any turnaround: “We have just one headline today, and that is that we are in a good place.” — James Rechtin, President and Chief Executive Officer · 2026-11-06 The numbers backed it up. Full-year adjusted EPS guidance rose to at least $9.50 from at least $9, cost trends were at the low end of the 7% to 8% range, and 2026 membership is performing in line to better than expected. The stock had already sniffed it out: shares jumped 13% on Oct. 9 after an improved Medicare Advantage rating and an analyst upgrade, and HUM is up 9.3% over the last 90 trading days.

But the real story is not the raise. It is the 2028 Stars over-earning that management can see and will not size. Humana's bonus-year 2028 member-weighted Star rating came in at 4.17, which Jim Rechtin said “significantly exceed our goal of top quartile” — James Rechtin, President and Chief Executive Officer · 2026-11-06 and approached the best Humana has ever posted. That is the kind of asset that normally gets capitalised into guidance. Instead, Rechtin drew a line: “we will manage the business assuming a level that approximates top quartile. That means our benefit structure and our broader cost structure must be tuned to and work closer to top quartile results, not at top decile.” — James Rechtin, President and Chief Executive Officer · 2026-11-06

This is not a new philosophy. In July, Rechtin defined the target precisely: “Top quartile is measured on a per member per month basis. It is Stars revenue, taking into account each of the different star ratings.” — James Rechtin, President and Chief Executive Officer · 2026-07-29 The goal of top quartile has been the operating anchor. What is new is that Humana is now above it by enough to generate a one-time tailwind — and is deliberately refusing to let that tailwind become the base case. That is the tension of this report.

No Known Headwinds, Except the Ones They're Pricing

For 2027, CFO Celeste Mellet was direct: “we, going into '27, don't have any known headwinds other than carrying the Stars headwind we have from this year.” — Celeste Mellet, Chief Financial Officer · 2026-11-06 The tailwinds are real: transformation savings, the J curves for Medicaid and PCO, a better product position, and fewer new members than 2026, which lowers year-one marketing and onboarding drag.

But the detail matters more than the headline. Core trend is expected at 8% to 9% next year versus 7% to 8% this year, and Part D trend is guided to 14% to 15%, driven by the health technology pipeline. That is not a soft-landing story. It is a pricing story. Mellet was explicit that the company cannot simply pad bids: “you have to be able to justify the costs that you price into your bids. You can't just add to be conservative.” — Celeste Mellet, Chief Financial Officer · 2026-11-06 Rechtin reframed the same point: “it's less about conservatism and it's more about discipline.” — James Rechtin, President and Chief Executive Officer · 2026-11-06

That distinction is the difference between a durable margin recovery and a one-year pricing grab. The Group MA recontracting has already improved 500 basis points excluding Stars, but the full benefit waits for 2028 Stars. Medicaid and the PCO business are still climbing their J-curves. PCO had pressure in one Florida geography, which Mellet said is ringed and not meaningful to the enterprise. So 2027 is a bridge year: no known headwinds, but no easy ones either.

The Balance Sheet Got Boring, in a Good Way

The quiet new story is capital structure. Two transactions close this quarter: the sale of Humana's minority interest in Gentiva for roughly $900 million in pretax proceeds, and a new BlackRock joint venture replacing the long-standing Welsh Carson JVs. The JV lowers the cost of capital and cuts JV-related liabilities. Mellet said it should drive “a reduction of approximately 130 basis points in the GAAP debt-to-cap ratio in the fourth quarter.” — Celeste Mellet, Chief Financial Officer · 2026-11-06 More important, Humana no longer needs to fund a 2027 put option that, if debt-funded, would have added another 130 basis points. That is real de-risking versus April, when Mellet said a Welsh Carson put would be “about $1 billion to $1.5 billion in 2027” — Celeste Mellet · 2026-04-29 and was included in the funding plan. The keyword debt to cap jumped to the top of Humana's keyword set for a reason.

The fundamentals show why the balance-sheet work matters. Revenue in the latest reported quarter was $40.9 billion, up 26% year over year, but the operating margin is only 3.3% and the net margin 1.7%. The equity is not cheap on depressed earnings: 36.9x trailing net income. The bull case is normalization, not today's multiple. Effective net cash of $29.5 billion provides flexibility, but the single biggest use of capital is funding insurance reserves as membership grows. Buybacks, as Mellet noted, are onerous to debt-to-cap. Capital return will be dividend-led and modest until earnings recover.

What Would Make This More Than a Stars Trade

Three things. First, Humana needs to quantify the 2028 tailwind or at least frame the sustainable earnings base at its Dec. 10 investor update. Rechtin said they will not be ready until late next year: “We will not be ready to quantify this until late next year or possibly even in the 2027 fourth quarter call.” — James Rechtin, President and Chief Executive Officer · 2026-11-06 That is defensible — competitor Stars scores will improve, the gap to top quartile will shrink, and membership mix is unknown — but it leaves the market underwriting a call option it cannot price.

And what we do know, and I'll just stress this again, is the tailwind will be sufficient. Even with all of the factors that I just described, it will be sufficiently large that we will not be able to productively invest all of it.

Second, the 2027 AEP has to convert early strength into membership growth. Management currently expects membership up for 2027, a reversal from the planned exits that dominated prior calls. Third, the high quality provider and value based care strategy must keep improving outcomes without giving away the Stars economics. The 30% capitated-provider offset is real: “Don't forget about the 30% offset with the value-based care providers.” — Celeste Mellet, Chief Financial Officer · 2026-11-06 A dollar of Stars upside is not a dollar of HUM EPS.

HUM also sits in the Medicare Advantage membership basket that has worked over the past year alongside CVS and CLOV. But its own tape is still a recovery, not a breakout: the full history shows a 23% drawdown from the 2022 peak, even with the recent 9.3% bounce. The market is voting that the worst is over. It is not yet voting that the windfall is fully valued. That is the gap management has chosen to leave open — for now.